|
HS Code |
338773 |
As an accredited 2,4-Dichloro-7-Bromoquinazoline factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 2,4-Dichloro-7-Bromoquinazoline prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
In the world of chemical synthesis, small differences in structure can set apart one compound from another in practical ways that count for researchers and industries alike. 2,4-Dichloro-7-Bromoquinazoline shows this principle in action. This molecule catches the eye of many working in medicinal chemistry, agrochemical development, and advanced material sciences due to its unique blend of reactivity and versatility. At first glance, it may look just like another quinazoline derivative, but its profile—marked by both chlorine and bromine substitutions—offers a distinct edge for those seeking new routes in drug design and molecular engineering.
With a molecular formula of C8H3BrCl2N2 and a firm spot in the quinazoline family, this compound reigns as a building block capable of spawning a range of functional molecules. Chemists know from hands-on experience what it means to work with intermediates that speed up syntheses or provide cleaner routes to desired targets. The placement of halogens on this core ring affects how the molecule behaves during substitution, making site-selective modification more accessible. This reactivity difference allows scientists to selectively swap out halogen atoms through palladium-catalyzed couplings or nucleophilic displacement—core techniques in organic labs striving for efficiency and clarity.
Get into the laboratory details, and practical concerns push to the forefront. In a world where time equals money, and product quality directly affects downstream outcomes, researchers often look for intermediates that help them move quickly and confidently. 2,4-Dichloro-7-Bromoquinazoline stands out for more than just theoretical reasons. The compound’s crystalline structure contributes to easier handling compared with sticky oils or volatile analogues. Its melting point, substantially higher than many other substituted quinazolines, gives it physical stability and extends its shelf life in storerooms that face fluctuating temperatures. Those who scale up reactions, even from gram to multi-kilogram batches, benefit from this robustness, cutting headaches associated with shipping losses or spoilage.
The chemistry underlying this compound’s popularity traces back to earlier days of drug discovery, where the quinazoline scaffold proved fertile ground for kinase inhibitors and other drugs targeting complex enzymes. Adding chlorine atoms at the 2 and 4 positions narrows down options for further modification, letting chemists make precise, predictable changes. The 7-bromo group, meanwhile, opens a door to Suzuki coupling and Buchwald-Hartwig amination reactions—a boon for anyone tweaking side chains on bioactive molecules or adding functional traces for diagnostics and imaging. Every medicinal chemist who wrestled with contamination or by-product headaches in late-stage synthesis knows the value of a clean, well-behaved building block like this one.
Many users compare 2,4-Dichloro-7-Bromoquinazoline to its monochloro or monobromo cousins and find the differences far from academic. Dual halogenation not only tunes the electronic properties of the ring system; it also delivers a molecule ready to handle two different chemical tactics at different positions. Unlike unsubstituted quinazolines—sometimes too reactive in unwanted ways—this doubly-chlorinated, brominated version avoids overactivity, letting scientists nudge the reaction one way or another based on what they need. For those who regularly use compounds where a single error can throw off weeks of work, these practical control points make all the difference.
In medicinal chemistry, scaffolds like 2,4-Dichloro-7-Bromoquinazoline are more than just theoretical starting points. Teams working on kinase inhibitors, particularly for oncology or inflammatory diseases, often trace their routes back to quinazoline frameworks, which have proved adaptable for fine-tuned receptor binding. Substituting specific groups at the 2, 4, and 7 positions lets biological evaluation move fast—sometimes uncovering a promising new compound after only a handful of elegant steps. Experienced project leaders often recommend starting with multipurpose intermediates that cut down on synthetic dead ends, helping teams dodge the dreaded loss of time when a lead candidate needs unexpected changes.
In agricultural research, chemical flexibility carries real-world consequences for productivity and environmental safety. Derivatives crafted from 2,4-Dichloro-7-Bromoquinazoline sometimes serve as key parts of herbicide candidates. The precise halogenation gives researchers a handle for crafting molecules with the right blend of potency and selectivity, reducing harm to off-target species. Field trials may demand hundreds of variations on a single scaffold, and having a starting material that reliably produces pure derivatives keeps things moving smoothly from lab bench to greenhouse to field plot.
Those in material science fields look to advanced aromatics for properties like fluorescence, charge transport, or chemical resistance. Highly substituted quinazolines allow engineers to test new devices—think organic semiconductors or optical sensors—without getting bogged down in by-product waste or compromised film quality. The physical stability and robust shelf presence of the product mean fewer surprises crop up during scale-up and device prototyping.
From my own rounds with intermediate screening in the lab, choice boils down to a mix of reliability, cost, and chemical versatility. Those who have handled less stable quinazolines or ones with sensitive functional groups know the pain of frequent restocking or unpredictable degradation. It only takes one fouled batch or sluggish reaction to make a person look for alternatives. Colleagues working in pharmaceutical development echo this, often pointing out the weeks shaved off development timelines when a trusted intermediate paves the way.
In side-by-side testing, 2,4-Dichloro-7-Bromoquinazoline regularly delivers higher yields during nucleophilic substitution compared with less substituted analogues. This performance stems from the electronic effect brought about by dual chlorine atoms, which draw electrons toward themselves, increasing the electrophilicity at specific positions on the ring. Mechanistic studies back up these anecdotes: more selective and efficient reactions, fewer unforeseen by-products, and easier purification by column chromatography or recrystallization. When dealing with tight deadlines or large compound libraries, these incremental gains translate to better overall outcomes.
Practical experience also weighs heavily with those concerned about cost and resource utilization. Industrial chemists often point to 2,4-Dichloro-7-Bromoquinazoline as a way to consolidate inventory, reducing the need for multiple, closely related starting materials that each require their own storage and hazard tracking. Consolidation translates to cost savings, fewer headaches for procurement teams, and more standardized training for workers, whether junior or senior.
Anyone who’s worked in scale-up knows regulations around chemical handling can shift overnight. 2,4-Dichloro-7-Bromoquinazoline’s solid-state profile reduces risks associated with inhalation or accidental spills, especially compared with more volatile intermediates that often flare alarms during inspections. It helps reduce environmental impact because solid intermediates are less prone to accidental releases and are easier to contain in modern safety protocols. This may seem like a small advantage, but ask any environmental safety officer and they’ll tell you—fewer liquid containment issues mean fewer nightmare scenarios after hours or during extreme weather.
Waste management also matters. Halogenated intermediates can present specific challenges for disposal, especially in countries with strict environmental codes. Experienced lab managers often recommend using intermediates like 2,4-Dichloro-7-Bromoquinazoline in multi-step syntheses because its efficiency cuts the number of required solvent washes and minimizes side-product formation. Smarter chemistry at the start leads to less hazardous waste in the end—something more organizations care about now that sustainability goals are pushing departments to justify their choices to auditors and the public.
A decade ago, before greener chemistry caught on, options for substituted quinazolines were narrower, and the choices often came down to what a supplier happened to have in stock. Now, people weigh the subtle performance differences between products, and 2,4-Dichloro-7-Bromoquinazoline claims a valued spot because of several tangible qualities. The dual chlorine and single bromo substitution creates a specific balance—strong electron-withdrawing power at key positions, and a site for further derivatization thanks to the bromine atom. This edge means scientists can steer the molecule toward either carbon-bonded or nitrogen-bonded transformations, which is helpful for rapidly generating libraries of analogues or targeting functional motifs for complex molecules.
Look at competitors—either the mono-halogenated alternatives or less selectively substituted quinazolines—and you find yourself stuck with more reaction steps, more protecting group strategies, or less stable intermediates. Over time, project managers in pharmaceutical R&D keep returning to 2,4-Dichloro-7-Bromoquinazoline because its performance in Suzuki and Buchwald-Hartwig couplings outpaces agents that lack the bromo group. I’ve seen teams move from the drawing board to first-stage biological assays in under a month, thanks to the quick installation of new side chains aided by the reliable reactivity of that 7-bromo position.
Every experienced chemist understands that the path from order to result is littered with potential pitfalls—shipment delays, unexpected impurities, and batch-to-batch variability can all throw a wrench into even the best-planned workflow. 2,4-Dichloro-7-Bromoquinazoline wins points in this arena thanks to its capacity for reliable purity and reproducible performance. Many suppliers now recognize that researchers measure not only technical specs but also the consistency delivered with each batch. In my lab days, spotting changes in melting point or impurity profile was always a red flag, and those who have run NMR checks on new deliveries will nod in agreement: slight formulation shifts can derail multi-million dollar projects.
With this particular compound, its robust crystalline structure and relatively high melting point boost storage life and ensure stability across different environmental conditions. Logistics teams find themselves breathing easier, knowing mid-summer shipments or longer storage intervals won’t degrade the product or surprise downstream users with an unexpected phase change or loss of reactivity.
Academic and industrial scientists consistently report favorable outcomes with 2,4-Dichloro-7-Bromoquinazoline in the chemical literature. One peer-reviewed study demonstrated improved yields—often up to 90 percent—when using it in Suzuki coupling reactions compared with other halogenated quinazolines. Another report focused on SNAr reactions, highlighting the enhanced selectivity for nucleophilic displacement at the correct position, tied directly to the combined influence of both chlorine atoms.
Looking over patent filings in the last decade, one trend becomes clear: researchers repeatedly cite the compound as a preferred intermediate in routes toward anti-cancer drugs, kinase inhibitors, and new pesticide candidates. This change from a minor building block to a linchpin in many synthetic routes signals a broad confidence in its utility and consistency. Whether working in a university, a startup, or a global pharmaceutical company, more chemists are leveraging published protocols that start from this specific molecule to compress their discovery timelines and streamline regulatory approval processes.
No product is immune from criticism. Some practitioners point to the challenge of removing residual halides due to the heavy substitution present in 2,4-Dichloro-7-Bromoquinazoline. This issue can complicate purification in the last stages of synthesis, where downstream toxicity from residual halogen can threaten project viability. Newer techniques, like advanced chromatographic methods or green solvent extractions, are closing the gap, but awareness and technical discipline matter more than ever.
Economic volatility sometimes affects halogenated intermediates, with the price of bromine and chlorine swinging based on global supply and regulatory changes. Forward-looking buyers often lock in longer-term supply agreements for key intermediates, including this one, to buffer against spikes that may hit project budgets. The value of investing in stable, reputable suppliers becomes more obvious every year, especially as tighter regulatory handling of halogen sources puts pressure on smaller producers.
Talking with chemists across several industries, I hear a common refrain: sustainability and safety aren't just buzzwords. They are shaping every decision, from material selection to waste disposal. Whoever adopts 2,4-Dichloro-7-Bromoquinazoline into research pipelines generally sees an uptick in synthetic efficiency, which leads to less solvent waste and fewer hazardous by-products. This greener footprint can strengthen a company’s standing with customers and regulators alike.
Training programs that help technicians recognize the handling and storage requirements of halogenated aromatics pay off. No one wants an expensive intermediate turning to dust or crust due to poor humidity control or packing mistakes. Good habits—sealed containers, minimal light exposure, controlled-temperature environments—extend the life and integrity of the product, and clear documentation ensures consistency from lab to plant scale.
Product stewardship also matters: as the chemical industry moves to more transparent supply chains, those who include clear, evidence-backed storage, use, and disposal guidelines foster trust within teams and with external auditors. Good habits around documentation help smooth inevitable conversations about environmental impact, and reduce surprises during third-party audits.
2,4-Dichloro-7-Bromoquinazoline stands out as a practical, adaptable intermediate in both academic and industrial settings. Its unique combination of halogenation offers tangible benefits—greater reactivity control, durable storage, and versatile downstream potential—that set it apart from both more simplistic and overly complex alternatives. Those working in medicinal chemistry, agricultural innovation, or advanced materials find that rare mix of reliability and reactivity worth the investment.
As the drive toward greener processes and more streamlined synthetic approaches continues, intermediates with the track record and adaptability of 2,4-Dichloro-7-Bromoquinazoline will only see their role expand. With firsthand experience and published evidence backing up its qualities, it’s clear this isn’t just another molecule on the shelf—it’s a cornerstone for modern chemical research and production.